GMP certification requirements in Chile, Cuba and Venezuela

Home/Reports | Posted 08/10/2021 post-comment0 Post your comment

The increasingly globalized nature of commerce allows manufacturers to outsource activities, such as procurement of raw materials overseas, where different regulatory requirements may exist. Thus, there is a need to ensure that the good manufacturing practices (GMP) guidelines adopted by the regulatory authorities (RAs) and international organizations (IOs) are harmonized and robust. A robust set of GMP guidelines helps in safeguarding public health by assuring the quality, safety and efficacy of the biopharmaceuticals [1].

07 AA011110

Consideration must be given to certain steps such as legalization of documents and the period in project timelines when submitting documents for marketing authorization in several countries in Latin America. This also includes a wide range of GMP certification requirements and variation in the need to present certification for only one product or for intermediates of that product or active pharmaceutical ingredient (API).

The requirements to present GMP certificate in drug products marketing authorization submissions are very briefly described below for Chile, Cuba and Venezuela.

Chile and Cuba
Local authorities in these countries require the submission of GMP certificate for the drug product and accept the document issued by the authority of the country where the manufacturing site is located.

Venezuela
The regulatory body in charge of approving medicines in Venezuela is the National Institute of Hygiene Rafael Rangel (Instituto Nacional de Higiene Rafael Rangel, INHRR).

INHRR requires the presentation of GMP certificate for the drug product and accepts the document issued by the authority of the country where the manufacturing site is located.

Considering local experience, although not defined in the requirements checklist, presentation of the API GMP certificate was required for a new molecule in the country.

This article is the last of a series of four articles on the certification of GMP requirements in different countries in Latin America.

Related articles
GMP certification requirements in Central American countries

GMP certification requirements in Andean Community countries

GMP certification requirements in Argentina, Brazil and Mexico

Biopharmaceuticals and biosimilars: manufacturing challenges

Biopharmaceuticals and biosimilars: challenges in manufacture, regulation and international harmonization of GMP

LATIN AMERICAN FORUM

The new section of the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish.

View this week’s headline article: Requisitos de certificación de BPF en Chile, Cuba y Venezuela

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

LATIN AMERICAN FORUM

Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de esta semana: Requisitos de certificación de BPF en Chile, Cuba y Venezuela

Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Foro Latinoamericano. Informe a colegas y amigos sobre esta nueva iniciativa. 

 

Reference
1. U.S. Food and Drug Administration. Facts about the current good manufacturing practices (CGMPs). 2018 [homepage on the Internet]. [cited 2021 Oct 8]. Available from: https://www.fda.gov/drugs/pharmaceutical-quality-resources/facts-about-current-good-manufacturing-practices-cgmps

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
The role of PD biomarkers in biosimilarity
Pharmacology MIT
Home/Reports Posted 03/12/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010